



THE 14th SUGIYAMA LABORATORY (RIKEN) OPEN SYMPOSIUM

“From Drug screening, selection, translation to clinical development”

Date : 12:30 - 17:50, October 11th, 2019

Venue : RIKEN Yokohama Main Office Building Hall

12:30-12:35 Opening remarks
Yuichi Sugiyama (Sugiyama Laboratory, RIKEN)

【Key note Lecture】

12:35-13:15 ADME Characterization and Application of Translational Modeling in Drug Discovery; impact, opportunities and challenges
Marjoleen Nijsen (AbbVie Inc.)

【Special lecture】

13:15-13:45 Translational and reverse translational research on pediatric liver diseases
Hisamitsu Hayashi (The University of Tokyo)

【Round table discussion on

“From Drug screening, selection, translation to clinical development”】

13:45-14:10 Prediction of major clearance pathway using in silico approach.
Kimio Tohyama (Takeda Pharmaceutical Company Limited)

14:10-14:35 Application of in silico ADME prediction in drug discovery stage.
Daisuke Sugiyama (DAIICHI SANKYO COMPANY, LIMITED)

14:35-15:00 Prediction of human hepatic clearance for OATP1B substrate drugs by in vitro-in vivo extrapolation approaches.
Yoshitane Nozaki (Eisai Co., Ltd.)

15:00-15:25 Coffee break

15:25-15:50 Extended Clearance Classification System (ECCS) approach in drug discovery - OAT2 contribution to hepatic clearance for ECCS1A compounds.
Emi Kimoto (Pfizer Inc.)

15:50-16:15 Pharmacokinetics and Pharmacogenomics Characterization of Compound X - From Discovery to Clinic.
Ryota Kikuchi (AbbVie Inc.)

16:15-16:40 Prediction and mechanistic evaluation of clinical DDI with transporter endogenous biomarkers.
Kenta Yoshida (Genentech inc.)



- 16:40-17:05 The Strategic implementation of MIDD in the early clinical development.
Akihiro Yamada (Astellas Pharma Inc.)
- 17:05-17:50 General discussion
Yuichi Sugiyama (Sugiyama Laboratory, RIKEN)
- 18:00-19:45 Banquet (Cafeteria at Yokohama RIKEN)

[This Symposium is a part of the RIKEN Symposium Series.]